Published in Mol Genet Genomics on February 18, 2010
A statistical framework for Illumina DNA methylation arrays. Bioinformatics (2010) 1.92
Methylation profiles reveal distinct subgroup of hepatocellular carcinoma patients with poor prognosis. PLoS One (2014) 1.51
Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips. Epigenetics (2012) 1.39
Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett (2012) 1.36
Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics (2011) 1.29
Correction of PCR-bias in quantitative DNA methylation studies by means of cubic polynomial regression. Nucleic Acids Res (2011) 1.08
Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma. PLoS One (2011) 1.05
IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma. BMC Gastroenterol (2010) 0.98
Comprehensive profiling of zebrafish hepatic proximal promoter CpG island methylation and its modification during chemical carcinogenesis. BMC Genomics (2011) 0.95
Clinical implications of DNA methylation in hepatocellular carcinoma. HPB (Oxford) (2011) 0.94
DNA methylation is altered in maternal blood vessels of women with preeclampsia. Reprod Sci (2012) 0.87
Discovery and validation of methylation markers for endometrial cancer. Int J Cancer (2014) 0.86
Patterns of cellular and HPV 16 methylation as biomarkers for cervical neoplasia. J Virol Methods (2012) 0.85
Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma. J Adv Res (2013) 0.82
MethyLight droplet digital PCR for detection and absolute quantification of infrequently methylated alleles. Epigenetics (2015) 0.82
ordinalgmifs: An R Package for Ordinal Regression in High-dimensional Data Settings. Cancer Inform (2014) 0.82
Role of histone deacetylase 9 in regulating adipogenic differentiation and high fat diet-induced metabolic disease. Adipocyte (2014) 0.79
Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma. World J Gastroenterol (2015) 0.77
Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis. Cancer Sci (2014) 0.76
Genistein potentiates the effect of 17-beta estradiol on human hepatocellular carcinoma cell line. Adv Biomed Res (2016) 0.76
A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets. Oncogene (2016) 0.75
A six-CpG panel with DNA methylation biomarkers predicting treatment response of chemoradiation in esophageal squamous cell carcinoma. J Gastroenterol (2016) 0.75
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
The role of chromatin during transcription. Cell (2007) 26.48
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
NCBI GEO: mining millions of expression profiles--database and tools. Nucleic Acids Res (2005) 17.61
Genome-scale identification of nucleosome positions in S. cerevisiae. Science (2005) 15.04
Cancer epigenetics comes of age. Nat Genet (1999) 12.63
MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res (2000) 9.30
Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol (2003) 9.10
High-throughput DNA methylation profiling using universal bead arrays. Genome Res (2006) 8.05
beadarray: R classes and methods for Illumina bead-based data. Bioinformatics (2007) 6.08
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet (2001) 3.96
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Human embryonic stem cells have a unique epigenetic signature. Genome Res (2006) 2.89
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol (2008) 2.24
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res (1999) 2.19
A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology (2006) 1.99
Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology (2008) 1.97
Expression profiling predicts outcome in breast cancer. Breast Cancer Res (2002) 1.81
Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade--results of an explorative CGH meta-analysis. Br J Cancer (2005) 1.64
Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis (2008) 1.57
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology (2005) 1.48
AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer (2008) 1.37
Aberrant methylation of gene promoters in cancer---concepts, misconcepts, and promise. J Natl Cancer Inst (2000) 1.35
Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res (2003) 1.34
Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. J Hepatol (2006) 1.22
Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res (2000) 1.22
Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem Biophys Res Commun (2006) 1.20
DNA methylation analysis by MethyLight technology. Methods (2001) 1.15
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol (2007) 1.14
APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol (2007) 0.99
Persistent infection of hepatitis B virus is involved in high rate of p16 methylation in hepatocellular carcinoma. Mol Carcinog (2006) 0.99
Predicting individual outcomes in hepatocellular carcinoma. Lancet (2004) 0.95
Hepatocellular carcinoma: current approaches to diagnosis and management. Intern Med J (2002) 0.91
Relationship of p16 methylation status and serum alpha-fetoprotein concentration in hepatocellular carcinoma patients. Clin Chem (2000) 0.89
Differentially expressed genes between early and advanced hepatocellular carcinoma (HCC) as a potential tool for selecting liver transplant recipients. Mol Med (2006) 0.88
Surveillance for hepatocellular carcinoma and early diagnosis. Clin Liver Dis (2007) 0.85
A new predictive factor for hepatocellular carcinoma based on two-dimensional electrophoresis of genomic DNA. Oncogene (2000) 0.80
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology (2004) 3.45
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg (2005) 2.64
Evaluation of quality-control criteria for microarray gene expression analysis. Clin Chem (2004) 2.28
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology (2011) 2.01
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 1.94
Living kidney donors requiring transplantation: focus on African Americans. Transplantation (2007) 1.92
Donor morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.90
MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl (2007) 1.86
Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis (2007) 1.78
Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl (2004) 1.76
Effect of hyponatraemia on outcomes following orthotopic liver transplantation. Liver Int (2009) 1.76
En bloc kidney transplantation from pediatric donors: comparable outcomes with living donor kidney transplantation. Transplantation (2011) 1.62
Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med (2008) 1.61
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2011) 1.59
Adult living donor versus deceased donor liver transplantation: a 10-year prospective single center experience. Ann Hepatol (2009) 1.44
Allograft TNFbeta and IL16 polymorphisms influence HCV recurrence and severity after liver transplantation. Liver Transpl (2006) 1.42
Adult living donor versus deceased donor liver transplantation: a 6-year single center experience. Am J Transplant (2005) 1.31
Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology (2007) 1.31
An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis (2005) 1.14
Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg (2010) 1.13
Cutaneous cryptococcosis in solid organ transplant recipients. Med Mycol (2010) 1.09
Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. Transplantation (2005) 1.05
Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation (2005) 1.02
Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation (2007) 1.01
A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl (2007) 0.99
Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation (2007) 0.97
Gene expression changes are associated with loss of kidney graft function and interstitial fibrosis and tubular atrophy: diagnosis versus prediction. Transplantation (2011) 0.95
Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis (2008) 0.95
Unrecognized pretransplant and donor‐derived cryptococcal disease in organ transplant recipients. Clin Infect Dis (2010) 0.94
Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother (2007) 0.94
Molecular pathways involved in loss of kidney graft function with tubular atrophy and interstitial fibrosis. Mol Med (2008) 0.94
Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int (2012) 0.92
Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation (2008) 0.92
Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl (2004) 0.90
Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation (2009) 0.90
Liver regeneration after living donor transplantation: adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2014) 0.89
Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation? Liver Transpl (2011) 0.88
Molecular pathways involved in loss of graft function in kidney transplant recipients. Expert Rev Mol Diagn (2010) 0.88
Evaluation of gene panel mRNAs in urine samples of kidney transplant recipients as a non-invasive tool of graft function. Mol Med (2007) 0.88
Differentially expressed genes between early and advanced hepatocellular carcinoma (HCC) as a potential tool for selecting liver transplant recipients. Mol Med (2006) 0.88
Incidence of prolonged length of stay after orthotopic liver transplantation and its influence on outcomes. Liver Transpl (2009) 0.87
Hepatocellular carcinoma in HCV-infected patients awaiting liver transplantation: genes involved in tumor progression. Liver Transpl (2004) 0.87
Identifying genes for establishing a multigenic test for hepatocellular carcinoma surveillance in hepatitis C virus-positive cirrhotic patients. Cancer Epidemiol Biomarkers Prev (2009) 0.86
Genes associated with progression and recurrence of hepatocellular carcinoma in hepatitis C patients waiting and undergoing liver transplantation: preliminary results. Transplantation (2007) 0.85
Proteomics and liver fibrosis: identifying markers of fibrogenesis. Expert Rev Proteomics (2009) 0.84
Reasons for non-use of recovered kidneys: the effect of donor glomerulosclerosis and creatinine clearance on graft survival. Transplantation (2004) 0.84
Study of mRNA growth factors in urinary cells of kidney transplant recipients as predictors of chronic allograft nephropathy. Transplantation (2005) 0.84
Identifying biomarkers as diagnostic tools in kidney transplantation. Expert Rev Mol Diagn (2011) 0.83
Hepatic artery thrombosis after liver transplantation and genetic factors: prothrombin G20210A polymorphism. Transplantation (2003) 0.83
Defining long-term outcomes with living donor liver transplantation in North America. Ann Surg (2015) 0.82
Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant (2002) 0.82
Bronchobiliary fistula after liver transplantation. J Comput Assist Tomogr (2004) 0.81
Pretransplant transcriptome profiles identify among kidneys with delayed graft function those with poorer quality and outcome. Mol Med (2011) 0.81
Hepatic disease biomarkers and liver transplantation: what is the potential utility of microRNAs? Expert Rev Gastroenterol Hepatol (2013) 0.81
Ex Vivo Perfusion With Adenosine A2A Receptor Agonist Enhances Rehabilitation of Murine Donor Lungs After Circulatory Death. Transplantation (2015) 0.81
Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int (2007) 0.81
Graft-versus-host disease after solid organ transplantation: a single center experience and review of literature. Ann Transplant (2012) 0.81
Is hepatic transplantation justified for primary liver cancer? J Surg Oncol (2007) 0.80
Identification of biomarkers to assess organ quality and predict posttransplantation outcomes. Transplantation (2012) 0.80
Comparison of two drug regimens upon clinical outcome among renal transplant recipients with positive flow cytometric crossmatches. Clin Transplant (2002) 0.80
Regulation of molecular pathways in ischemia-reperfusion injury after liver transplantation. Transplantation (2013) 0.80
Quality assessment of microarray data in a multicenter study. Diagn Mol Pathol (2009) 0.80
Engraftment measurement in human liver tissue after liver cell transplantation by short tandem repeats analysis. Cell Transplant (2004) 0.80
In vitro sensitivity of commercial scanners to microchips of various frequencies. J Am Vet Med Assoc (2008) 0.79
MiRNAs in kidney transplantation: potential role as new biomarkers. Expert Rev Mol Diagn (2013) 0.79
Donor selection for adult-to-adult living donor liver transplantation: well begun is half done. Transplantation (2013) 0.79
Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation (2014) 0.79
Identifying genes progressively silenced in preneoplastic and neoplastic liver tissues. Int J Comput Biol Drug Des (2010) 0.79
Psychosocial Outcomes 3 to 10 Years After Donation in the Adult to Adult Living Donor Liver Transplantation Cohort Study. Transplantation (2016) 0.79
Enabling altruism: evaluating the adult living liver donor. Liver Transpl (2007) 0.78